Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Albireo Pharma Inc (ALBO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7226
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The company’s lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase III clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc (ALBO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Albireo Pharma Inc, Medical Equipment, Deal Details 10
Equity Offering 10
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 10
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 12
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 14
Albireo Pharma Inc – Key Competitors 15
Albireo Pharma Inc – Key Employees 16
Albireo Pharma Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 07, 2018: Albireo reports second quarter 2018 financial results 18
May 17, 2018: Albireo Provides First Quarter 2018 Business Update 20
Mar 15, 2018: Albireo Reports Fourth Quarter and Year-End 2017 Financial Results 21
Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 23
Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 25
May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 27
Mar 14, 2017: Albireo Reports 2016 Financial Results 29
Corporate Communications 31
Oct 10, 2018: Albireo appoints Simon Harford as chief financial officer and treasurer 31
Jul 25, 2018: Albireo appoints Patrick Horn as Chief Medical Officer 32
Jun 18, 2018: Albireo Names Jason G. Duncan As General Counsel And Secretary 33
Jun 08, 2018: Albireo Names Anne Klibanski and Stephanie Okey As Board Directors 34
Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Albireo Pharma Inc, Medical Equipment, Key Facts, 2017 2
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Deals By Market, 2012 to YTD 2018 8
Albireo Pharma Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Albireo Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 10
Albireo Pharma Raises USD74.8 Million in Public Offering of Shares 12
Albireo Pharma Raises USD19.2 Million in Public Offering of Shares 14
Albireo Pharma Inc, Key Competitors 15
Albireo Pharma Inc, Key Employees 16
Albireo Pharma Inc, Other Locations 17
Albireo Pharma Inc, Subsidiaries 17

List of Figures
Albireo Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Albireo Pharma Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Albireo Pharma Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Albireo Pharma Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Albireo Pharma Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oriental Food Industries Holdings Berhad:企業の戦略・SWOT・財務情報
    Oriental Food Industries Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Oriental Food Industries Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Nasdaq Inc (NDAQ):企業の財務・戦略的SWOT分析
    Nasdaq Inc (NDAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Coslight Technology International Group Ltd (1043):企業の財務・戦略的SWOT分析
    Coslight Technology International Group Ltd (1043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Hudson Pacific Properties Inc:企業のM&A・事業提携・投資動向
    Hudson Pacific Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hudson Pacific Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Indequity Group Limited:企業の戦略・SWOT・財務分析
    Indequity Group Limited - Strategy, SWOT and Corporate Finance Report Summary Indequity Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Helix BioPharma Corp (HBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company's proprietary broad anti-cancer therape …
  • Essentra plc (ESNT):企業の財務・戦略的SWOT分析
    Essentra plc (ESNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • VAMED AG:企業の戦略・SWOT・財務情報
    VAMED AG - Strategy, SWOT and Corporate Finance Report Summary VAMED AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Regulus Therapeutics Inc (RGLS)-医療機器分野:企業M&A・提携分析
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a developer of microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its products are used for the ther …
  • Takara Bio Inc (4974):製薬・医療:M&Aディール及び事業提携情報
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Electricidade de Mocambique EP-エネルギー分野:企業M&A・提携分析
    Summary Electricidade de Mocambique EP (EDM) is a state owned vertically integrated energy utility that generates, distributes, transmits, and commercializes electricity. The company produces electricity from hydro and thermal sources. It has interests in Lichinga, Cuamba, Corumana, Chicamba, and Ma …
  • Genisphere LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Genisphere LLC (Genisphere) is a nanotechnology company that provides DNA-based targeted drug delivery solutions. The company utilizes its proprietary 3DNA platform which enables the application in gene delivery, biologics, small molecules, and RNAi therapeutics. It develops pipeline product …
  • Morphotek Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Morphotek Inc (Morphotek), a subsidiary of Eisai Inc, is a clinical-stage biotechnology company that develops monoclonal antibodies, antibody drug conjugates, and bispecific antibodies to treat cancer, inflammatory and infectious diseases. Its pipeline product portfolio includes farletuzumab …
  • Global Marine Systems Ltd:電力:M&Aディール及び事業提携情報
    Summary Global Marine Systems Limited (Global Marine), a subsidiary of Bridgehouse Marine Limited, is a marine technology and engineering company. It provides submarine cable installation, maintenance and engineering services. Its capabilities include project management, subsea cable installation, s …
  • Bankinter, S.A.:企業の戦略・SWOT・財務情報
    Bankinter, S.A. - Strategy, SWOT and Corporate Finance Report Summary Bankinter, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Neurocrine Biosciences Inc (NBIX):企業の財務・戦略的SWOT分析
    Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Avacta Group Plc (AVCT):企業の財務・戦略的SWOT分析
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …
  • Global Investment House KPSC (GLOBAL):企業の財務・戦略的SWOT分析
    Global Investment House KPSC (GLOBAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Puracap Pharmaceutical LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Puracap Pharmaceutical LLC (PuraCap) is a drug development company that offers prescription generics and OTC products. The company provides over the counter soft gels and oral solid dosage healthcare products for upper respiratory, pain relief, cough and cold, sleep aid, gastrointestinal, an …
  • Dedeman Hotels & Resorts International:企業の戦略・SWOT・財務分析
    Dedeman Hotels & Resorts International - Strategy, SWOT and Corporate Finance Report Summary Dedeman Hotels & Resorts International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆